Conning Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Conning reduced its stake in Amgen by 6.01% during the most recent quarter end. The investment management company now holds a total of 149,984 shares of Amgen which is valued at $25,599,269 after selling 9,584 shares in Amgen , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Amgen makes up approximately 1.06% of Conning’s portfolio.

Other Hedge Funds, Including , Oakwood Capital Managementca reduced its stake in AMGN by selling 252 shares or 0.71% in the most recent quarter. The Hedge Fund company now holds 35,026 shares of AMGN which is valued at $5,978,238. Amgen makes up approx 1.51% of Oakwood Capital Managementca’s portfolio.Trust Co Of Toledo Na Oh reduced its stake in AMGN by selling 50 shares or 1.75% in the most recent quarter. The Hedge Fund company now holds 2,805 shares of AMGN which is valued at $478,757. Amgen makes up approx 0.14% of Trust Co Of Toledo Na Oh’s portfolio.Security National Trust Co boosted its stake in AMGN in the latest quarter, The investment management firm added 87 additional shares and now holds a total of 10,181 shares of Amgen which is valued at $1,686,686. Amgen makes up approx 0.60% of Security National Trust Co’s portfolio. Evanson Asset Management added AMGN to its portfolio by purchasing 1,388 company shares during the most recent quarter which is valued at $226,591. Amgen makes up approx 0.07% of Evanson Asset Management’s portfolio.F&v Capital Management reduced its stake in AMGN by selling 455 shares or 1.04% in the most recent quarter. The Hedge Fund company now holds 43,410 shares of AMGN which is valued at $6,993,351. Amgen makes up approx 5.10% of F&v Capital Management’s portfolio.

Amgen opened for trading at $171.57 and hit $172.26 on the upside on Friday, eventually ending the session at $172.03, with a gain of 0.44% or 0.75 points. The heightened volatility saw the trading volume jump to 31,21,594 shares. Company has a market cap of $129,232 M.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Investors should note that on Jul 22, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced Aug 15, 2016 as the ex-dividend date and fixed the record date on Aug 17, 2016. The payable date has been fixed on Sep 8, 2016.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.